Introduction {#sec1-1}
============

*Amavata* is one of the most difficult to cure (*Krichhrasadhya*) diseases mentioned in *Ayurveda*. The main pathological factor in the development of this disease is "*Ama*". *Ama* is a substance which is produced in the body due to weakness of *agni*.\[[@ref1]\] This *Ama* is then carried by "*Vata*" and travels throughout the body and gets accumulated in the joints, which is the seat of "*Kapha*". As this process continuous, all the joints are gradually affected, which results in severe pain and swelling in the joints.\[[@ref2]\] When "*Pitta*" also gets associated, it causes burning sensation around the joints. Clinically, it is very much close to rheumatoid arthritis described in modern medical science, which is a chronic inflammatory autoimmune disease involving multiple joints of the body. In modern medicine, the treatment of the disease includes steroids and immunomodulator drugs together with nonsteroidal anti-inflammatory drugs (NSAIDs).\[[@ref3]\] Long-term use of these drugs has many adverse effects on the other systems of the body. But the use of Ayurvedic drugs having *Dipana, Pachana, Srotoshodhana* and *Rasayana* actions like *Pippali* (*Piper longum*) can be beneficial to these patients. Further, it is free from the serious adverse effects as compared to the modern conventional therapy, provided it is given in proper dose and regimen.

*Pippali* has *Dipana*, *Pachana* and *Rasayana* actions\[[@ref4]\] and is helpful in alleviating Ama from the body which is the basic pathological factor in this disease, i.e. rheumatoid arthritis. It is one of the *Rasayana* drugs described in *Charaka samhita*.\[[@ref5]\] The use of *Pippali* in gradually increasing and tapering dose known as *Vardhamana Pippali* is more effective because it can be administered in its maximum doses without any discomfort to the patient. The present clinical study was carried out in 73 clinically diagnosed cases of *Amavata* (rheumatoid arthritis) to evaluate the role of *Vardhamana Pippali* *Rasayana* in *Amavata*.

Aims and objectives {#sec2-1}
-------------------

To evaluate the efficacy of *Vardhamana Pippali* in patients of *Amavata* (rheumatoid arthritis)To provide a safe, economical and effective remedy to the patients of *Amavata*

Materials and Methods {#sec1-2}
=====================

Clinical study {#sec2-2}
--------------

The clinical study was carried out in 73 clinically diagnosed patients of *Amavata* registered in IPD of JS Ayurvedic College and PD Patel Ayurvedic Hospital, Nadiad.

Inclusion criteria {#sec2-3}
------------------

The criteria of inclusion of patients were based on the signs and symptoms of *Amavata* (rheumatoid arthritis). They are

morning stiffness (\>1 hour);arthritis of three or more joints andsymmetrical arthritis.

The patients were selected randomly irrespective of their age, sex, religion, etc.

Exclusion criteria {#sec2-4}
------------------

The patients having any other chronic systemic illness, metabolic diseases like gout, with severe deformities and endocrinological diseases were excluded from the study.

Criteria for assessment {#sec2-5}
-----------------------

All the symptoms were given score to assess the effect of the treatment objectively. Erythrocyte sedimentation rate (ESR) was recorded before and after the treatment. The scoring pattern is as given in [Table 1](#T1){ref-type="table"}.

###### 

Gradation of symptoms for assessment
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Criteria for assessment of the effect of *Vardhamana Pippali Rasayana* on symptoms of *Amavata* {#sec2-6}
-----------------------------------------------------------------------------------------------

Unchanged: Less than 25% relief in symptoms

Improved: 25-49% relief in symptoms

Markedly improved: 50-99% relief in symptoms

Complete remission: 100% relief in symptoms

Administration of the drug {#sec2-7}
--------------------------

Drug: *Pippali Churna* (powder of *P. longum*)

Powder of *Pippali* (*P. longum*) in *Vardhamana Krama*, i.e. starting the dose from 1 g on the first day, twice a day with honey, was given . It was increased by 1 g daily up to a maximum dose of 5 g twice a day. The maximum dose, i.e. 5 g, was given for 5 days and then it was tapered by 1 g daily to a dose of 1 g twice a day. Patients were kept on *Mudga yusha*. Total duration of the treatment was 15 days. All the patients were given *Mridu Virechana* with *Eranda taila* (Castor oil) in doses of 30-40 ml with hot water according to their *Koshtha* and the strength on next day after the completion of the *Vardhamana Pippali* regimen. Any change in symptoms and ESR was recorded after the completion of regimen.

Results and Observations {#sec1-3}
========================

Tables [2](#T2){ref-type="table"}--[6](#T6){ref-type="table"} show the results and observations of the study. Total 43 patients (58.9%) were in the age group of 41-60 years, followed by 24 patients (32.8%) in the age group of 21-40 years. 4 patients (5.47%) were aged more than 60 years and only 2 patients (2.73%) were less than 20 years of age \[[Table 2](#T2){ref-type="table"}\]. Total 57 (78.08%) patients were females, whereas 16 (21.90%) patients were males \[[Table 3](#T3){ref-type="table"}\]. Maximum, i.e. 41% patients, were suffering from the disease for less than 1 year, 38.35% patients were having duration of illness 1-3 years and 20.54% patients were having symptoms of the disease for more than 1 year \[[Table 4](#T4){ref-type="table"}\].Improvement in the symptom of pain in joints was 50.56% which is statistically highly significant. Stiffness in the joints decreased by 48.57% which is statistically highly significant.

###### 

Age wise distribution of 73 registered patients of *Amavata*
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###### 

Sex wise distribution of 73 registered patients of *Amavata*
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###### 

Chronicity wise distribution of 73 registered patients of *Amavata*
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###### 

Effect of *Vardhamana Pippali Rasayana* on the symptoms of *Amavata* in 73 registered patients of *Amavata*
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###### 

Effect of *Vardhamana Pippali Rasayana* on ESR in 73 registered patients of *Amavata*
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Swelling in the joints also decreased by 53.22% which is also statistically highly significant. The improvement in the symptom of restriction in the movements in the joints was 46.43% which is statistically highly significant \[[Table 5](#T5){ref-type="table"}\]. A significant decrease in ESR (17.67%) was observed in the patients registered for the study after the completion of treatment course, which is statistically highly significant \[[Table 6](#T6){ref-type="table"}\].

During the course of the treatment, none of the patients showed any adverse reactions.

Discussion {#sec1-4}
==========

The basic pathology in the *Amavata* is the formation of *Ama* in the body due to *Agnimandya*,\[[@ref1]\] followed by vitiation of all the three *doshas*, predominantly *Vata*. Rheumatoid arthritis is an autoimmune disorder and it can be equated with *Amavata*. *Balabhramsha* is described as one of the clinical consequences of *Ama*. *Balabhrmasha* may be interpreted as *Ayathaprarvrtti* of *Bala*. *Bala* is very well accepted as an immune component by Ayurvedic scholars. Hence, *Balabhrmasha* or *Ayathaprarvrtti* of *Bala* can be understood as altered immune activity or autoimmune disorders. The use of *Pippali* in increasing and tapering doses is known as "*Vardhamana Pippali*". It is very effective because it can be administered in its maximum doses without any discomfort to the patient. Of all the 73 patients registered for the present study, 43 patients (58.9%) were in the age group of 21-40 years and most of them (78%) were females. Most of the patients were having duration of illness 1-3 years. The use of *Vardhamana Pippali Rasayana* in 73 registered cases of *Amavata* caused 50.56% relief from the symptom of pain in joints, 48.7% relief from the symptom of stiffness in the joints, 53.25% relief from the swelling in joints and 46.20% relief from restriction of movements. All these results were found to be statistically highly significant (*P* \< 00.001). A remarkable reduction (17.76%) in ESR was also noticed in the patients registered for the current clinical study and this result is also statistically highly significant (*P* \< 0.001). Further, no specific side/adverse effects were noticed in any of the patients registered for the present clinical trial.

*Pippali* is one of the *Rasayana* drugs described in *Ayurveda*. It has *Agnidipana* and *Amapachana* actions and is helpful in the alleviation of *Ama* from the body which is the main pathological factor in *Amavata*, i.e. rheumatoid arthritis. *Pippali* alleviates *Ama*, the factor responsible for *Balabhrmsha* or development of autoimmune disorders in the body, resulting in the correction in immune system activities. *Pippali* has rasayana and immunomodulator actions. Thus, because of all these actions together, it plays an important role in the *Samprapti-vighatana* of the *Amavata*, i.e. rheumatoid arthritis. Further, the drug is very much economical and the therapy is very cost-effective also.

Conclusion {#sec1-5}
==========

On the basis of observations and discussion of this study, the following conclusions can be drawn.

*Vardhamana Pippali Rasayana* has a lot of beneficial effects in the patients of *Amavata*.It is free from any side effects.It is also very much cost-effective.
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